$NVLX has acquired worldwide exclusive rights to the cellulose-based live cell-encapsulation technology, also known as Cell-in-a-Box™, and described above, from SG Austria Pte. Ltd. for the development of treatments for any and all types of cancer. The rights to use the cancer drug-activating cells that will be part of Nuvilex’s treatment for advanced pancreatic cancer (see Pancreatic Cancer section of this website) were also acquired. The acquisition of rights to use the Cell-in-a-Box™ technology for the development of treatments for insulin-dependent diabetes has recently been completed